Arthneeti
TP

Torrent Pharmaceuticals Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Torrent Pharmaceuticals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹4,896
Market cap₹1.8L Cr
P/E82.4
Updated23 Aug 2026
Read5 min read

The short version

India business is expected to continue outperforming market growth, driven by chronic therapies, new launches, and improved field force productivity. India business expected to continue outperforming market growth with focus on chronic therapies and new launches driving volume growth. - Brazil showing strong double-digit constant currency growth with healthy volume growth and mid-single digit price increases. - US business optimistic on ramping up filings (4-5 this year, aiming for 10 next year, 15 thereafter) with intent to return to sustainable profitability, but no large new CAPEX planned. - Germany facing supply disruption; expected normalization by Q4 FY'26; growth guidance currently withheld. - Overall revenue growth for Q2 FY'26 was 14%, with Operating EBITDA up 15% and margin at 32.8%. - Leverage is low at 0.45x net debt to EBITDA. - CAPEX expected at Rs.

From Torrent Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • India business is expected to continue outperforming market growth, driven by chronic therapies, new launches, and improved field force productivity.
  • India Q2 volume growth was 3.7% versus 0% market growth; price growth at 5.5%, indicating sustained demand.
  • Brazil is showing strong growth (15% vs market 7%) supported by new product launches and volume pickups in existing mega brands.
  • The semaglutide opportunity in Brazil is regarded as very significant, with filings under priority review.
  • US business is ramping up ANDA filings (4-5 this year, up to 15 in subsequent years), aiming to return to profitability without major CAPEX.
  • Germany growth is currently impacted by supplier disruption; normalization expected from Q4.
  • Field force expansions ongoing: India aims for 7,000 reps by FY end, supporting volume growth.
  • Launches in new therapies planned in India and Brazil, with some pipeline products waiting ANVISA approval.
  • Overall, growth driven by chronic therapies, new product launches, and international market expansions.

Profitability & Margins

See what Torrent Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For H1 FY'26, total CAPEX was roughly Rs. 200 crores.
  • Full year CAPEX for FY'26 is expected to be around Rs. 300 crores.
  • Over the next three years, average annual CAPEX is projected to be between Rs. 250 to 300 crores.
  • No large CAPEX investments planned in the US generics space; current infrastructure supports upcoming product launches.
  • Future expansions primarily in chronic and sub-chronic divisions in India with field force growth.
  • For Brazil’s and India’s GLP-1 (semaglutide) launches, existing diabetes and cardio teams are managing, with plans to expand teams later, but no immediate headcount increase planned in the next 18 months.
  • Strategic investment ongoing with the JB Pharma acquisition expected to close by January 2026; synergy details to be shared post-closing.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Torrent Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript does not explicitly mention current or expected order book or pending orders for Torrent Pharmaceuticals Limited. Key points related to business outlook include: - India business showing robust growth with expanding field force and new therapy launches. - Brazil business with strong growth and a rich pipeline of 65 molecules filed awaiting ANVISA approval. - US generic filings ramping up from 4-5 ANDAs currently to around 10 next year and eventually up to 15. - Semaglutide filings underway in Brazil, awaiting approval; expected to be a material opportunity when launched. - Supply disruptions in Germany are expected to normalize by Q4. - JB Pharma acquisition closing expected by January 2026, with synergy details to follow post-closing. No specific data on order book or pending orders was disclosed during this call.

Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹4.2K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Torrent Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Alivus Life Sciences Ltd (Q2 FY26)

    Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…

  • Solara Active Pharma Sciences Ltd (Q2 FY26)

    Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…

  • Sun Pharmaceutical Industries Ltd (Q2 FY26)

    India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…

  • Zydus Lifesciences Ltd (Q2 FY26)

    Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Zydus Lifesciences Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Torrent Pharmaceuticals Ltd Q2 FY26 results?

India business is expected to continue outperforming market growth, driven by chronic therapies, new launches, and improved field force productivity. India business expected to continue outperforming market growth with focus on chronic therapies and new launches driving volume growth. - Brazil showing strong double-digit constant currency growth with healthy volume growth and mid-single digit price increases. - US business optimistic on ramping up filings (4-5 this year, aiming for 10 next year, 15 thereafter) with intent to return to sustainable profitability, but no large new CAPEX planned. - Germany facing supply disruption; expected normalization by Q4 FY'26; growth guidance currently withheld. - Overall revenue growth for Q2 FY'26 was 14%, with Operating EBITDA up 15% and margin at 32.8%. - Leverage is low at 0.45x net debt to EBITDA. - CAPEX expected at Rs.

What is Torrent Pharmaceuticals Ltd share price analysis?

Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.

Is Torrent Pharmaceuticals Ltd planning capital expenditure?

For H1 FY'26, total CAPEX was roughly Rs.

Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.